Literature DB >> 10459874

Effects of chronic treatment with simvastatin on endothelial dysfunction in spontaneously hypertensive rats.

M Alvarez de Sotomayor1, C Pérez-Guerrero, M D Herrera, E Marhuenda.   

Abstract

OBJECTIVE: To investigate the effects of chronic treatment with simvastatin (SV) on endothelium-dependent relaxation and ouabain-induced contractions in aortic rings from spontaneously hypertensive rats (SHR), comparing with normotensive Wistar-Kyoto rats (WKY).
METHODS: After a 12-week period of administration of 1 or 2 mg/kg SV to SHR and WKY, systolic blood pressure (SBP) and vascular reactivity in endothelium-intact aortic rings were assessed.
RESULTS: Relaxation in response to acetylcholine (ACh) in WKY remained unaltered, but in SHR treated with 1 mg/kg SV, enhanced ACh-induced relaxation (P<0.05 versus untreated SHR) reached values observed in untreated WKY. The 2 mg/kg treatment also improved ACh relaxation (P<0.01 and P<0.05 versus untreated SHR and WKY respectively). Inhibiting cyclo-oxygenase (COX) with indomethacin (INDO) improved ACh relaxation in SHR (P<0.05) but not in WKY, independent of treatment with SV. Inhibition of nitric oxide synthase (NOS) with N(G)-nitro-L-arginine (L-NOARG) abolished ACh relaxations in all cases (P<0.001). The result was unaltered when combining INDO plus L-NOARG. SV treatment also decreased ouabain-induced contractions in endothelium-intact aortic rings from SHR, diminishing the percentage effect of contraction from 64.56+/-2.95 (untreated SHR) to 26.98+/-7.06 and 38.10+/-8.21 (1 and 2 mg/kg treated SHR respectively). Response to ouabain in WKY was not significantly affected by SV treatment
CONCLUSIONS: Chronic treatment of SHR with SV improves endothelium-dependent ACh relaxation of the aortic rings, probably by an NO-involving mechanism more than by inhibiting contractile COX-derived factors. An improvement in endothelial modulation of ouabain-induced contractions was also observed after treatment with SV in SHR, which might be due to an inhibition of a calcium-sodium exchanger.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10459874     DOI: 10.1097/00004872-199917060-00008

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat.

Authors:  M Alvarez De Sotomayor; M D Herrera; E Marhuenda; R Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

2.  Improvement of age-related endothelial dysfunction by simvastatin: effect on NO and COX pathways.

Authors:  Maria Alvarez de Sotomayor; Concepción Pérez-Guerrero; M Dolores Herrrera; Luis Jimenez; Roberto Marín; Elisa Marhuenda; Ramaroson Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  Chronic ouabain treatment increases the contribution of nitric oxide to endothelium-dependent relaxation.

Authors:  R Aras-López; J Blanco-Rivero; R Hernanz; A M Briones; L V Rossoni; M Ferrer; M Salaices; G Balfagón
Journal:  J Physiol Biochem       Date:  2008-06       Impact factor: 4.158

4.  Vascular Metabolism as Driver of Atherosclerosis: Linking Endothelial Metabolism to Inflammation.

Authors:  Kim E Dzobo; Katie M L Hanford; Jeffrey Kroon
Journal:  Immunometabolism       Date:  2021-05-17

Review 5.  The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation.

Authors:  Paolo Gelosa; Mauro Cimino; Alice Pignieri; Elena Tremoli; Uliano Guerrini; Luigi Sironi
Journal:  Vasc Health Risk Manag       Date:  2007

6.  Swimming exercise changes hemodynamic responses evoked by blockade of excitatory amino receptors in the rostral ventrolateral medulla in spontaneously hypertensive rats.

Authors:  Cristiana A Ogihara; Gerhardus H M Schoorlemmer; Maria de Fátima M Lazari; Gisele Giannocco; Oswaldo U Lopes; Eduardo Colombari; Monica A Sato
Journal:  Biomed Res Int       Date:  2014-02-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.